Guggenheim raised the firm’s price target on AbbVie (ABBV) to $214 from $212 and keeps a Buy rating on the shares after updating its company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback